Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases

Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the hereditary forms or as a consequence of acquired conditions. Thanks to advances in imaging techniques and the...

Full description

Saved in:
Bibliographic Details
Published in:European heart journal Vol. 42; no. 16; p. 1554
Main Authors: Garcia-Pavia, Pablo, Rapezzi, Claudio, Adler, Yehuda, Arad, Michael, Basso, Cristina, Brucato, Antonio, Burazor, Ivana, Caforio, Alida L P, Damy, Thibaud, Eriksson, Urs, Fontana, Marianna, Gillmore, Julian D, Gonzalez-Lopez, Esther, Grogan, Martha, Heymans, Stephane, Imazio, Massimo, Kindermann, Ingrid, Kristen, Arnt V, Maurer, Mathew S, Merlini, Giampaolo, Pantazis, Antonis, Pankuweit, Sabine, Rigopoulos, Angelos G, Linhart, Ales
Format: Journal Article
Language:English
Published: England 21.04.2021
Subjects:
Amyloidosis - diagnosis
Amyloidosis - therapy
Cardiomyopathies - diagnosis
Cardiomyopathies - therapy
Heart
Heart Diseases - diagnosis
Heart Diseases - therapy
Humans
Myocardium
TTR
Treatment
Cardiac amyloidosis
Transthyretin
Amyloidosis
AL
Diagnosis
ISSN:1522-9645, 1522-9645
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the hereditary forms or as a consequence of acquired conditions. Thanks to advances in imaging techniques and the possibility of achieving a non-invasive diagnosis, we now know that cardiac amyloidosis is a more frequent disease than traditionally considered. In this position paper the Working Group on Myocardial and Pericardial Disease proposes an invasive and non-invasive definition of cardiac amyloidosis, addresses clinical scenarios and situations to suspect the condition and proposes a diagnostic algorithm to aid diagnosis. Furthermore, we also review how to monitor and treat cardiac amyloidosis, in an attempt to bridge the gap between the latest advances in the field and clinical practice.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1522-9645
1522-9645
DOI:10.1093/eurheartj/ehab072